Explain this page
Arphra AIPlain-English read on Spero Therapeutics, Inc.’s valuation06-17today
- Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)4d
- Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)4d
- Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update39d
- Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update39d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +8.06% | -22.18% | -15.24% | -3.80% | -1.72% | -2.15% | -22.18% | +56.16% | -84.34% | -80.17% | -80.17% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$2.30
Bid
$2.20
10,000 sh
Ask
$2.50
81 sh
Spread
$0.300
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)globenewswire.com·Jun 17, 2026
- Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)globenewswire.com·Jun 17, 2026
- Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Updateglobenewswire.com·May 13, 2026
- Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Updateglobenewswire.com·May 13, 2026
- Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026globenewswire.com·May 05, 2026
Peers
No peer list available for SPRO.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|